Stockhead on MSN
Biocurious: Behind Optiscan’s quest to ditch biopsies and bring pathology into the modern era
With the rise of robotic and minimally invasive surgery and other innovations, medicine has moved into the 21st century.
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback